Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028021

Enrollment

Registered

2022-03-07

Start date

2021-04-16

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: 177Lutetium PSMA RLT

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients between 18 and 99 years of age - Fulfilment of the standard criteria for a 177Lu-PSMA RLT - Low-risk accessibility of a PSMA-positive lesion by percutaneous biopsy

Exclusion criteria

Exclusion criteria: - Persons who are placed in an institution by court order or by order of the authorities. - Persons who are in a dependent relationship or employment relationship with the sponsor or investigator. - Severe psychiatric illnesses - Patients with congenital bleeding disorders (e.g. von Willebrand disease).

Design outcomes

Primary

Measure	Time frame
A. Is it possible to map intratumoural heterogeneity of metastatic castration-resistant prostate carcinoma based on different metabolic activity in positron emission tomography (PET) (cohort A)? B. Can adaptive resistance mechanisms of metastatic castration-resistant prostate cancer be identified from metastatic biopsies before and after 177Lu-PSMA-RLT (Cohort B)?	—

Secondary

Measure	Time frame
Can tumour-specific mutations in circulating cell-free DNA (ctDNA) be detected as plasma markers?	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026